Literature DB >> 22699808

Co-expression of VEGF and CA9 in ovarian high-grade serous carcinoma and relationship to survival.

Emma Williams1, Stewart Martin, Robert Moss, Lindy Durrant, Suha Deen.   

Abstract

Poor prognosis in ovarian high-grade serous carcinoma (HGSC) is largely related to resistance to chemotherapy. Tumour hypoxia is known to be associated with chemotherapy resistance. Stabilisation of hypoxia-inducible factor-1α upregulates the expression of downstream genes such as carbonic anhydrase 9 (CA9) and vascular endothelial growth factor (VEGF). This study was undertaken to analyse the hypoxia profile as indicated by the co-expression of VEGF and CA9 and its correlation with survival. VEGF and CA9 expressions were examined in tissue microarray of 97 cases of ovarian high-grade serous carcinoma using immunohistochemistry. High expression of either VEGF or CA9, individually, was associated with decreased overall survival (p = 0.006 and p = 0.05 respectively). Combined high expression of both markers, to give a 'hypoxia profile', was associated with chemotherapy resistance (p = 0.036) and showed worse overall survival with a significant p value (p = 0.001). Using multivariate analysis, hypoxia profile was an independent prognostic factor for overall survival (p = 0.028). The combined high expression CA9 and VEGF phenotype, described as high hypoxia profile group, was significantly associated with increased resistance to chemotherapy and poor overall survival. This group may benefit from combined targeted therapy for effective response in ovarian HGSC.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22699808     DOI: 10.1007/s00428-012-1252-9

Source DB:  PubMed          Journal:  Virchows Arch        ISSN: 0945-6317            Impact factor:   4.064


  33 in total

1.  Responses to salvage chemotherapy in ovarian cancer: a critical need for precise definitions of the treated population.

Authors:  M Markman; W Hoskins
Journal:  J Clin Oncol       Date:  1992-04       Impact factor: 44.544

2.  Analysis of DNA sequences in forty-year-old paraffin-embedded thin-tissue sections: a bridge between molecular biology and classical histology.

Authors:  D Shibata; W J Martin; N Arnheim
Journal:  Cancer Res       Date:  1988-08-15       Impact factor: 12.701

3.  Hypoxia-inducible expression of tumor-associated carbonic anhydrases.

Authors:  C C Wykoff; N J Beasley; P H Watson; K J Turner; J Pastorek; A Sibtain; G D Wilson; H Turley; K L Talks; P H Maxwell; C W Pugh; P J Ratcliffe; A L Harris
Journal:  Cancer Res       Date:  2000-12-15       Impact factor: 12.701

4.  Expression of transmembrane carbonic anhydrases IX and XII in ovarian tumours.

Authors:  P Hynninen; L Vaskivuo; J Saarnio; H Haapasalo; J Kivelä; S Pastoreková; J Pastorek; A Waheed; W S Sly; U Puistola; S Parkkila
Journal:  Histopathology       Date:  2006-12       Impact factor: 5.087

5.  Estrogen receptor analyses. Correlation of biochemical and immunohistochemical methods using monoclonal antireceptor antibodies.

Authors:  K S McCarty; L S Miller; E B Cox; J Konrath; K S McCarty
Journal:  Arch Pathol Lab Med       Date:  1985-08       Impact factor: 5.534

6.  Validation of tissue microarray technology in ovarian carcinoma.

Authors:  Daniel G Rosen; Xuelin Huang; Michael T Deavers; Anais Malpica; Elvio G Silva; Jinsong Liu
Journal:  Mod Pathol       Date:  2004-07       Impact factor: 7.842

7.  Tumor oxygenation predicts for the likelihood of distant metastases in human soft tissue sarcoma.

Authors:  D M Brizel; S P Scully; J M Harrelson; L J Layfield; J M Bean; L R Prosnitz; M W Dewhirst
Journal:  Cancer Res       Date:  1996-03-01       Impact factor: 12.701

8.  Expression of carbonic anhydrase IX (CA IX), a hypoxia-related protein, rather than vascular-endothelial growth factor (VEGF), a pro-angiogenic factor, correlates with an extremely poor prognosis in esophageal and gastric adenocarcinomas.

Authors:  Ann Driessen; Willy Landuyt; Sylvia Pastorekova; Johnny Moons; Laurence Goethals; Karin Haustermans; Philippe Nafteux; Freddy Penninckx; Karel Geboes; Toni Lerut; Nadine Ectors
Journal:  Ann Surg       Date:  2006-03       Impact factor: 12.969

9.  Immunohistochemical study of colorectal tumors for expression of a novel transmembrane carbonic anhydrase, MN/CA IX, with potential value as a marker of cell proliferation.

Authors:  J Saarnio; S Parkkila; A K Parkkila; K Haukipuro; S Pastoreková; J Pastorek; M I Kairaluoma; T J Karttunen
Journal:  Am J Pathol       Date:  1998-07       Impact factor: 4.307

Review 10.  Diagnostic, prognostic and therapeutic implications of carbonic anhydrases in cancer.

Authors:  C P S Potter; A L Harris
Journal:  Br J Cancer       Date:  2003-07-07       Impact factor: 7.640

View more
  15 in total

1.  Evaluation of a hypoxia regulated gene panel in ovarian cancer.

Authors:  Amanda F Baker; Scott W Malm; Ritu Pandey; Cindy Laughren; Haiyan Cui; Denise Roe; Setsuko K Chambers
Journal:  Cancer Microenviron       Date:  2015-05-22

2.  CA9 overexpression is an independent favorable prognostic marker in intrahepatic cholangiocarcinoma.

Authors:  Mijin Gu
Journal:  Int J Clin Exp Pathol       Date:  2015-01-01

3.  Topiramate exhibits anti-tumorigenic and metastatic effects in ovarian cancer cells.

Authors:  Guangxu Xu; Ziwei Fang; Leslie H Clark; Wenchuan Sun; Yajie Yin; Rong Zhang; Stephanie A Sullivan; Arthur-Quan Tran; Weimin Kong; Jiandong Wang; Chunxiao Zhou; Victoria L Bae-Jump
Journal:  Am J Transl Res       Date:  2018-06-15       Impact factor: 4.060

4.  The embryonic transcription factor Brachyury confers chordoma chemoresistance via upregulating CA9.

Authors:  Jiao Jian; Nanzhe Zhong; Dongjie Jiang; Lei Li; Yan Lou; Wang Zhou; Su Chen; Jianru Xiao
Journal:  Am J Transl Res       Date:  2018-03-15       Impact factor: 4.060

5.  Cytokines as Prognostic Biomarkers of Epithelial Ovarian Cancer (EOC): A Systematic Review and Meta-Analysis.

Authors:  Moh Nailul Fahmi; Heru Pradjatmo; Indwiani Astuti; Ricvan Dana Nindrea
Journal:  Asian Pac J Cancer Prev       Date:  2021-02-01

6.  Sulforaphane reduces molecular response to hypoxia in ovarian tumor cells independently of their resistance to chemotherapy.

Authors:  Michal Pastorek; Veronika Simko; Martina Takacova; Monika Barathova; Maria Bartosova; Luba Hunakova; Olga Sedlakova; Sona Hudecova; Olga Krizanova; Franck Dequiedt; Silvia Pastorekova; Jan Sedlak
Journal:  Int J Oncol       Date:  2015-05-05       Impact factor: 5.650

7.  Acidic extracellular microenvironment and cancer.

Authors:  Yasumasa Kato; Shigeyuki Ozawa; Chihiro Miyamoto; Yojiro Maehata; Atsuko Suzuki; Toyonobu Maeda; Yuh Baba
Journal:  Cancer Cell Int       Date:  2013-09-03       Impact factor: 5.722

8.  Evidence for a time-dependent association between FOLR1 expression and survival from ovarian carcinoma: implications for clinical testing. An Ovarian Tumour Tissue Analysis consortium study.

Authors:  M Köbel; J Madore; S J Ramus; B A Clarke; P D P Pharoah; S Deen; D D Bowtell; K Odunsi; U Menon; C Morrison; S Lele; W Bshara; L Sucheston; M W Beckmann; A Hein; F C Thiel; A Hartmann; D L Wachter; M S Anglesio; E Høgdall; A Jensen; C Høgdall; K R Kalli; B L Fridley; G L Keeney; Z C Fogarty; R A Vierkant; S Liu; S Cho; G Nelson; P Ghatage; A Gentry-Maharaj; S A Gayther; E Benjamin; M Widschwendter; M P Intermaggio; B Rosen; M Q Bernardini; H Mackay; A Oza; P Shaw; M Jimenez-Linan; K E Driver; J Alsop; M Mack; J M Koziak; H Steed; C Ewanowich; A DeFazio; G Chenevix-Trench; S Fereday; B Gao; S E Johnatty; J George; L Galletta; E L Goode; S K Kjær; D G Huntsman; P A Fasching; K B Moysich; J D Brenton; L E Kelemen
Journal:  Br J Cancer       Date:  2014-10-30       Impact factor: 7.640

9.  DNA hypomethylation-mediated overexpression of carbonic anhydrase 9 induces an aggressive phenotype in ovarian cancer cells.

Authors:  Hye Youn Sung; Woong Ju; Jung-Hyuck Ahn
Journal:  Yonsei Med J       Date:  2014-11       Impact factor: 2.759

10.  Hormone-receptor expression and ovarian cancer survival: an Ovarian Tumor Tissue Analysis consortium study.

Authors:  Weiva Sieh; Martin Köbel; Teri A Longacre; David D Bowtell; Anna deFazio; Marc T Goodman; Estrid Høgdall; Suha Deen; Nicolas Wentzensen; Kirsten B Moysich; James D Brenton; Blaise A Clarke; Usha Menon; C Blake Gilks; Andre Kim; Jason Madore; Sian Fereday; Joshy George; Laura Galletta; Galina Lurie; Lynne R Wilkens; Michael E Carney; Pamela J Thompson; Rayna K Matsuno; Susanne Krüger Kjær; Allan Jensen; Claus Høgdall; Kimberly R Kalli; Brooke L Fridley; Gary L Keeney; Robert A Vierkant; Julie M Cunningham; Louise A Brinton; Hannah P Yang; Mark E Sherman; Montserrat García-Closas; Jolanta Lissowska; Kunle Odunsi; Carl Morrison; Shashikant Lele; Wiam Bshara; Lara Sucheston; Mercedes Jimenez-Linan; Kristy Driver; Jennifer Alsop; Marie Mack; Valerie McGuire; Joseph H Rothstein; Barry P Rosen; Marcus Q Bernardini; Helen Mackay; Amit Oza; Eva L Wozniak; Elizabeth Benjamin; Aleksandra Gentry-Maharaj; Simon A Gayther; Anna V Tinker; Leah M Prentice; Christine Chow; Michael S Anglesio; Sharon E Johnatty; Georgia Chenevix-Trench; Alice S Whittemore; Paul D P Pharoah; Ellen L Goode; David G Huntsman; Susan J Ramus
Journal:  Lancet Oncol       Date:  2013-07-09       Impact factor: 41.316

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.